OakChart

Onconetix Inc

ONCOHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.76+0.29 (8.36%)
2026-11-12 05:00 CET
Market cap
2.21 USD m
Revenue, TTM
0.65 USD m
Net income, TTM
-10.20 USD m
Free cash flow, TTM
-10.31 USD m
EPS diluted, TTM
-1,991.00
P/E
-
Compare

Price

ONCO against its 20, 50 and 200-day averages
2050200
0.00250.00500.00750.001,000.002.4M4.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ONCOclose 3.7620-day 4.9250-day 6.40200-day 107.193.76

99.8% under the 52-week high of 1,610.00 on 10 Dec 2025. 52-week low 3.15 on 10 Nov 2026. Last 15 sessions, 148.3% high to low

Volume 0.18× normal · the line is the 50-bar volume average

Profile

ONCO
52-week range, 0% of the way up
3.151,610

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.

Employees8
IPOFeb 18, 2022
Beta2.64
ATR, 14d1.14
Rel volume0.18
Inst own9.14%

Snapshot

6 groups

Valuation

Index-
Market Cap2.21M
Enterprise Value-3.54M
Income-10.20M
Sales0.65M
Book/sh35.50
Cash/sh10.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOFeb 18, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S3.40
P/B0.11
P/C0.37
P/FCF-
EV/EBITDA-
EV/Sales-5.45
Quick Ratio2.14
Current Ratio2.21
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1991.00
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y83.59% 52.21%
Sales past 3/5Y- -
EPS Y/Y TTM99.22%
Sales Y/Y TTM-51.33%
EPS Q/Q99.46%
Sales Q/Q-83.92%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own9.14%
Inst Trans-
ROA-57.37%
ROE-102.87%
ROIC-75.63%
Gross Margin80.40%
Oper. Margin-1190.29%
Profit Margin-1578.79%
SMA20-23.56%
SMA50-41.23%
SMA200-96.49%
Trades-

Technical

Shs Outstand0.38M
Shs Float-
Short Float-
Short Ratio0.24
Short Interest0.10M
52W High1610.00 -99.77%
52W Low3.15 19.37%
Volatility39.95% 21.66%
ATR (14)1.14
RSI (14)40.76
Beta2.64
Rel Volume0.18
Avg Volume402.52K
Volume73,180

Performance

Perf Week-42.88%
Perf Month-32.25%
Perf Quarter-57.39%
Perf Half Y-90.28%
Perf YTD-99.52%
Perf Year-99.72%
Perf 3Y-100.00%
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close3.47
Price3.76
Change %8.36%

Peers

Mkt cap
TickerCompanyMkt cap
CDIOCardio Diagnostics Holdings Inc5.68M
KAPAKairos Pharma Ltd1.72M
VERUVeru Inc36.49M
CAICaris Life Sciences Inc7.02B
ANIXAnixa Biosciences Inc96.65M
KSCPKnightscope Inc9.44M
RRRichtech Robotics Inc213.33M
KITTNauticus Robotics Inc2.06M
SERVServe Robotics Inc278.15M
PDYNPalladyne AI Corp170.71M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HRT FINANCIAL LP10% OwnerApr 21 '26Sale0.6949,71034,30033,649Apr 22 02:59 PM
HRT FINANCIAL LP10% OwnerApr 17 '26Buy0.7334,63625,284177,821Apr 21 03:41 PM
HRT FINANCIAL LP10% OwnerApr 20 '26Sale0.7594,46270,84683,359Apr 21 03:41 PM
HRT FINANCIAL LP10% OwnerApr 16 '26Sale0.7353,86739,323143,185Apr 21 03:41 PM
HRT FINANCIAL LP10% OwnerApr 15 '26Buy0.7692,55470,341197,052Apr 16 02:30 PM
HRT FINANCIAL LP10% OwnerApr 14 '26Buy0.7774,35057,250104,498Apr 16 02:30 PM

News

latest 14 of 200
  • Realbotix Provides Update on Nasdaq Listing Timeline (Business Wire) -48.49%
  • Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement (GlobeNewswire) +18.92%
  • Onconetix Announces Reverse Stock Split (GlobeNewswire)
  • Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition (GlobeNewswire)
  • CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition (GlobeNewswire) -15.73%
  • Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition (GlobeNewswire)
  • Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events (GlobeNewswire) +9.60%
  • Realbotix Reports Financial Results for Q3-2026 (Business Wire) -7.91%
  • Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series (GlobeNewswire) -10.08%
  • Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG (GlobeNewswire) +20.42%
  • Realbotix Corp. Provides Corporate Structure and Operations Update (Business Wire)
  • Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation (GlobeNewswire)
  • Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District (GlobeNewswire) -6.54%
  • Onconetix, Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -61.56%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2023Q22023-08-14-306,000--733,7200.00--
2023Q12023-05-12-306,000-348,500-304,1640.000.002
2022Q42023-03-09-340,000-450,500-358,3600.000.002
2022Q32022-11-10-459,000--458,4390.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-1,870,000--1,853,0000.00-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2023Q3S2023-08-021000.000.000.00
2023Q3S2023-08-011000.000.000.00
2023Q3S2023-07-311000.000.000.00
2023Q3S2023-07-301000.000.000.00
2023Q3S2023-07-291000.000.000.00
2023Q3S2023-07-261000.000.000.00
2023Q3S2023-07-251000.000.000.00
2023Q3S2023-07-241000.000.000.00
2023Q3S2023-07-231000.000.000.00
2023Q3S2023-07-221000.000.000.00
2023Q3S2023-07-191000.000.000.00
2023Q3S2023-07-181000.000.000.00
2023Q3S2023-07-171000.000.000.00
2023Q3S2023-07-161000.000.000.00

Estimate history

EPS, annual-169541-332265-622353-1872431-3716625.001-911703.628-8281.49-1991.0047
Period2019202020212022202320242025TTM
EPS, quarterly-1095735-124537.75-107184.575-22717.95-2379.07-3124.831817.205-670.595-12.785
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000.0582.5240.8150.65
Period2019202020212022202320242025TTM
Sales, quarterly0.7050.4070.7120.1020.1060.3040.3040.0210.017
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0000000.0030.379
Period2019202020212022202320242025MRQ
Shares, quarterly0000.0010.0020.0030.0030.0280.379
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.650.822.520.060.000.000.000.00
Cost of Goods Sold Incl. D&A0.130.181.741.200.010.000.000.00
Gross Profit0.520.630.78-1.14-0.01-0.00-0.00-0.00
Selling, General and Administrative Excl. Other8.216.988.9114.7413.473.411.620.88
Research and Development0.08-0.070.151.954.131.330.520.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.69-6.34-8.13-15.88-13.48-3.42-1.62-0.88
Interest Expense0.310.751.410.670.000.00-0.00
Unusual Expense-1.233.4950.3720.87-0.060.000.000.00
Net Income Before Taxes-10.20-14.03-59.74-37.42-13.42-3.42-1.60-0.82
Income Taxes0.000.00-1.05-0.010.000.000.000.00
Consolidated Net Income-10.20-14.03-58.69-37.41-13.42-3.42-1.60-0.82
Net Income From Continuing Operations-10.20-14.03-58.69-37.41-13.42-3.42-1.60-0.82
Net Income-10.20-15.53-58.90-37.41-13.52-4.04-2.16-1.10
EPS (Recurring)-49.32-6,979.69-365,954.21-2,265,201.16-1,878,392.46-622,344.85-332,256.89-169,541.50
EPS (Basic, Before Extraordinaries)-1,991.00-8,281.49-911,703.63-3,716,625.00-1,872,431.00-622,353.00-332,265.00-169,541.00
EPS (Diluted)-1,991.00-8,281.49-911,703.63-3,716,625.00-1,872,431.00-622,353.00-332,265.00-169,541.00
EBITDA-7.67-6.33-7.40-15.84-13.47-3.41-1.62-0.88
Non-Operating Income (Expense)-3.43-3.450.170.000.000.000.020.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.040.060.350.261.970.130.330.00
Price To Sales Ratio3.921.790.6957.95----
Gross Margin80.4077.6230.93-1,950.17----
Operating Margin-1,190.29-778.16-322.14-27,161.98----
Net Margin-1,578.79-1,904.77-2,333.39-63,986.48----
Shares Outstanding0.380.000.000.000.000.000.000.00
Market Capitalization2.212.217.413.5316.1616.16--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.020.020.300.300.110.100.710.41
Cost of Goods Sold Incl. D&A0.010.020.060.030.040.060.170.33
Gross Profit0.00-0.000.250.270.070.050.540.08
Selling, General and Administrative Excl. Other2.252.091.532.341.411.702.512.72
Research and Development0.000.050.02-0.00-0.110.02-0.11
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.24-2.09-1.28-2.07-1.34-1.65-1.97-2.65
Interest Expense0.000.000.000.300.220.220.250.38
Unusual Expense0.622.10-7.823.860.796.6628.260.90
Net Income Before Taxes-2.87-4.215.67-8.78-2.37-8.55-30.36-3.88
Income Taxes0.000.000.000.000.000.00-0.92-0.06
Consolidated Net Income-2.87-4.215.67-8.78-2.37-8.55-29.44-3.83
Net Income From Continuing Operations-2.87-4.215.67-8.78-2.37-8.55-29.44-3.83
Net Income-2.87-4.215.67-8.78-2.70-9.72-29.64-3.83
EPS (Recurring)-10.84-436.2761.67-2,162.84-1,894.89-11,810.57-35,653.05-104,085.32
EPS (Basic, Before Extraordinaries)-12.78-670.601,817.20-3,124.83-2,379.07-22,717.95-107,184.58-124,537.75
EPS (Diluted)-12.78-670.601,817.20-3,124.83-2,379.07-22,717.95-107,184.58-124,537.75
EBITDA-2.24-2.09-1.28-2.07-1.34-1.65-1.85-2.44
Non-Operating Income (Expense)0.00-0.02-0.87-2.55-0.02-0.010.130.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.010.020.000.010.030.030.270.04
Price To Sales Ratio3.921.272.983.572.040.742.933.63
Gross Margin25.13-7.7181.5888.5566.2045.1075.9418.54
Operating Margin-13,112.09-9,748.80-422.06-681.45-1,259.62-1,626.32-276.99-650.32
Net Margin-16,748.27-19,643.361,867.51-2,892.70-2,536.24-9,560.15-4,163.73-940.72
Shares Outstanding0.380.030.000.000.000.000.000.00
Market Capitalization2.214.112.434.854.812.877.4143.23

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments5.220.654.5525.751.934.316.05
Short Term Receivables0.390.100.150.040.150.010.01
Inventories0.150.060.360.000.000.000.00
Other Current Assets0.310.140.770.470.230.288E-06
Total Current Assets6.070.955.8426.262.324.606.06
Net Property, Plant & Equipment0.090.180.210.010.010.020.01
Total Investments and Advances0.000.000.000.000.000.000.00
Long-Term Note Receivable0.000.25-----
Intangible Assets18.5527.0581.090.000.000.000.00
Deferred Tax Assets0.010.031.30----
Other Assets0.230.000.380.040.760.200.01
Total Assets24.9428.4688.8226.313.084.816.08
Short Term Debt Incl. Current Port. of LT Debt0.0213.579.690.000.000.000.00
Accounts Payable1.763.795.300.000.000.070.02
Other Current Liabilities7.350.932.203.921.640.000.06
Total Current Liabilities9.1418.2917.193.921.640.070.08
Long Term Debt0.020.000.190.000.000.000.00
Provision for Risks Charges0.000.280.560.000.000.000.00
Deferred Tax Liabilities0.010.034.38----
Other Liabilities0.000.000.860.000.000.010.01
Total Liabilities9.1718.6023.183.921.640.080.08
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.001.0764.240.000.000.000.00
Common Equity15.768.79-5.6022.391.454.736.00
Total Shareholders Equity15.779.8658.6322.391.454.736.00
Accumulated Minority Interest0.000.007.010.000.000.000.00
Total Equity15.779.8665.6422.391.454.736.00
Total Liabilities & Stockholders Equity24.9428.4688.8226.313.084.816.08
Book Value Per Share5,052.7631,792.03-426,590.302,493,222.07222,577.08728,363.75922,946.94
Tangible Book Value Per Share-892.43-66,007.15-6,601,309.542,493,220.93222,577.04728,363.62922,946.78
Full-Time Employees87231211--
Price to Book Ratio0.110.840.340.630.63--
Return on Assets-52.56-100.09-64.99-91.31-86.55-29.37-
Return on Equity-109.51-171.37-92.34-112.61-110.59-29.81-
Return on Invested Capital-88.86-595.19-63.59-59.94-236.24-33.79-13.70
Quick Ratio0.650.050.326.691.4166.9479.98
Current Ratio0.660.050.346.691.4166.9479.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-10.20-14.03-58.69-37.41-13.42-3.42-1.60-0.82
Depreciation0.010.020.730.040.010.000.000.00
Other Funds (Non Cash)1.886.7649.6522.172.180.150.330.00
Funds from Operations-8.31-7.26-9.35-15.20-11.24-3.26-1.26-0.82
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.00-2.42-1.541.622.541.21-0.47-0.01
Cash from Operating Activities-10.31-9.68-10.90-13.58-8.70-2.04-1.73-0.83
Capital Expenditures0.000.00-0.03-0.06-0.01-0.00-0.01-0.00
Net Assets From Acquisitions0.000.000.00-6.080.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.00-3.570.000.000.000.00
Other Sources0.000.000.001.060.000.000.000.00
Cash from Investing Activities0.000.00-0.03-8.65-0.01-0.00-0.01-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock20.2020.233.492.0432.53-0.330.006.93
Repurchase of Common Pref Stock0.000.000.00-0.060.000.000.000.00
Sale of Common Pref Stock20.2020.233.492.0932.53-0.330.006.93
Proceedsfrom Stock Options19.8220.233.482.0916.06-0.330.006.93
Issuance or Reduction of Debt, Net-4.56-5.783.65-1.000.000.000.00-0.05
Change in Long Term Debt-4.71-5.78-1.350.000.000.000.000.00
Issuance of Long Term Debt0.861.340.000.000.000.000.000.00
Reduction of Long Term Debt-5.57-7.11-1.350.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.00-0.000.000.000.000.000.00
Other Financing Activities Uses-0.00-0.00-0.000.000.000.000.000.00
Cash from Financing Activities15.6414.457.141.0432.53-0.330.006.88
Exchange Rate Effect0.33-0.20-0.13-0.00----
Net Change in Cash5.664.57-3.91-21.2023.82-2.38-1.746.05
Free Cash Flow-10.31-9.68-10.92-13.58-8.71-2.05-1.74-0.83
Preferred Dividends (Cash Flow)---0.00----
Deferred Taxes & Investment Tax Credit-0.00-1.05-0.010.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments5.943.725.220.840.281.58
Short Term Receivables0.050.100.390.040.060.07
Inventories0.210.140.150.150.150.16
Other Current Assets0.320.380.310.270.430.62
Total Current Assets6.524.336.071.300.932.42
Net Property, Plant & Equipment0.070.070.090.050.070.15
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets9.6210.2018.5518.1818.1216.21
Deferred Tax Assets--0.01---
Other Assets0.230.230.230.150.000.00
Total Assets16.4314.8324.9419.6819.1218.78
Short Term Debt Incl. Current Port. of LT Debt0.170.270.020.178.759.85
Accounts Payable1.841.531.761.802.582.58
Other Current Liabilities0.921.267.3514.331.361.61
Total Current Liabilities2.943.079.1416.3012.6914.04
Long Term Debt0.010.020.020.000.000.00
Provision for Risks Charges0.000.000.000.000.070.22
Deferred Tax Liabilities--0.01---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.963.089.1716.3012.7714.26
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.440.52
Common Equity13.4711.7515.763.375.913.99
Total Shareholders Equity13.4711.7515.773.386.354.52
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity13.4711.7515.773.386.354.52
Total Liabilities & Stockholders Equity16.4314.8324.9419.6819.1218.78
Book Value Per Share35.50426.355,052.761,080.992,928.604,616.12
Tangible Book Value Per Share10.1556.00-892.43-4,743.54-6,052.45-14,123.92
Full-Time Employees--8---
Price to Book Ratio0.110.350.151.440.810.72
Return on Assets-57.37-57.73-52.56-120.44-112.45-119.65
Return on Equity-102.87-119.29-109.51-263.57-254.09-237.69
Return on Invested Capital-21.27-35.8235.91-260.19-37.34-189.18
Quick Ratio2.141.370.650.070.060.16
Current Ratio2.211.410.660.080.070.17

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.87-4.215.67-8.78-2.37-8.55
Depreciation0.000.010.000.000.000.00
Other Funds (Non Cash)0.632.13-7.666.781.036.61
Funds from Operations-2.23-2.08-1.99-2.00-1.34-1.93
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.32-0.04-1.11-1.18-0.07-0.07
Cash from Operating Activities-1.92-2.12-3.09-3.18-1.41-2.00
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.00----
Change in Capital Stock4.270.386.259.300.973.71
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.270.386.259.300.973.71
Proceedsfrom Stock Options4.270.006.259.300.973.71
Issuance or Reduction of Debt, Net-0.100.250.30-5.01-0.22-0.84
Change in Long Term Debt0.000.000.30-5.01-0.22-0.84
Issuance of Long Term Debt0.000.000.460.400.380.10
Reduction of Long Term Debt0.000.00-0.16-5.41-0.60-0.94
Net Financing Active Other Cash Flow-0.00-0.000.000.00-0.000.00
Other Financing Activities Uses-0.00-0.000.000.00-0.000.00
Cash from Financing Activities4.170.636.554.290.742.87
Exchange Rate Effect-0.02-0.010.93-0.56-0.630.06
Net Change in Cash2.23-1.504.380.55-1.290.93
Free Cash Flow-1.92-2.12-3.09-3.18-1.41-2.00

Revenue breakdown

Development Service2024: 2.28M 2025: 1.65K
Other Revenues2025: 587.88K
Product Sales2024: 249.03K 2025: 225.84K
European Union2024: 2.44M 2025: 796.59K
Non European Union2024: 23.84K 2025: 18.78K
United States2024: 63.12K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.1M-372.64K
2026-10-157.45%0.0M0.5M287.13K
2026-09-3011.20%0.0M0.4M225.86K
2026-09-153.10%0.0M0.4M63.77K
2026-08-314.27%0.0M0.4M53.33K
2026-08-143.86%0.0M0.4M91.90K
2026-07-314.98%0.0M0.4M90.47K
2026-07-153.32%0.0M0.4M103.71K
2026-06-301.68%0.0M0.4M128.89K
2026-06-150.51%0.0M0.4M121.43K
2026-05-295.40%0.0M0.1M116.97K
2026-05-150.59%0.0M0.1M75.30K
2026-04-3090.14%0.0M0.0M75.14K
2026-04-1539.46%0.0M0.0M57.32K
2026-03-31117.24%0.0M0.0M12.83K
2026-03-138.91%0.0M0.0M653
2026-02-273.01%0.0M0.0M424
2026-02-1312.60%0.0M0.0M386
2026-01-308.51%0.0M0.0M148
2026-01-159.88%0.0M0.0M83

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-04SEC
2026-11-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-11-068-KCurrent report2026-11-04SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-27425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-268-KCurrent report2026-10-22SEC
2026-10-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-238-KCurrent report2026-10-22SEC
2026-10-23425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-16ARSAnnual report to security holders. 2025-12-31SEC
2026-10-07DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-10SEC
2026-09-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-17SEC
2026-09-14DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-148-KCurrent report2026-09-11SEC
2026-09-14425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-08424B3SEC
2026-09-03EFFECTEffectiveness filing by commission orderSEC
2026-09-03425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-31S-1/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-12S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-298-KCurrent report2026-07-28SEC
2026-07-27SCHEDULE 13GSEC
2026-07-07425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-06-24425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-06-17424B3SEC
2026-06-16EFFECTEffectiveness filing by commission orderSEC
2026-06-15CORRESPSEC
2026-06-12UPLOADUpload SubmissionSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-04152.87K3144.47K3
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP1.39%
GEODE CAPITAL MANAGEMENT, LLC0.52%
XTX Topco Ltd0.37%
UBS Group AG0.35%
StoneX Group Inc.0.35%
SBI Securities Co., Ltd.0.01%
Tower Research Capital LLC0.00%
HOLLENCREST CAPITAL MANAGEMENT0.00%
MORGAN STANLEY0.00%
BARCLAYS PLC0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.57%

OakChart. ONCO. Cached 15 minutes.

Some panels did not load: ratings.